The trend of outsourcing activities in the pharmaceutical domain is rising as companies find value in acquiring additional competencies essential for successful drug development and commercialization. Besides providing extended expertise & assisting in improved cash flow management, outsourcing brings significant manufacturing advantages, including reducing investment risks. Notably, in the context of early-stage technologies and products, establishing expensive in-house capabilities entails substantial risks across the product development phases. At the same time, outsourcing serves as a risk-averse alternative.
In addition, a limited understanding of the required scale for current and future product offerings or market penetration poses significant hurdles in designing and scaling manufacturing for in-house production. Consequently, the preference for outsourcing has grown as an effective strategy until market demand for products becomes well-established and understood. Moreover, the expansion of cell and gene therapies is significantly impacting the sterile injectable market. As these innovative treatments gain traction, there is a growing need for specialized manufacturing capabilities that comply with stringent regulatory requirements.
Overall, the sterile injectable contract development and manufacturing market is on an upward trajectory, fueled by rising demand for biologics, chronic disease management, outsourcing trends, technological advancements, and the emergence of innovative therapies. These factors collectively position CDMOs as critical players in meeting the evolving needs of the pharmaceutical industry.
Competitive Landscape: Sterile Injectable CDMOs Report Coverage |
||||
Market Outlook |
Company Categorization |
Service Heat Map Analysis |
Competitive Assessment Analysis |
List of Key CDMOs by Region |
Company Overview |
Service Benchmarking |
Financial Reporting |
Major Deals and Strategic Alliances Analysis |
SWOT Analysis |
The competitive assessment analysis is based on company revenue size and service penetration of key service providers in the market. Players such as Baxter and Boehringer Ingelheim International GmbH secured high market size and service offerings. The medium segment covers Ajinomoto Bio-Pharma and Fresenius Kabi Contract Manufacturing (Fresenius Kabi AG), among others. Fareva Group, Vetter Pharma International GmbH, PCI Pharma Services, Siegfried AG, Recipharm AB, and others are in the low category owing to minimum revenue generation and service penetration.
The sterile injectable contract development and manufacturing organization market is undergoing transformative changes driven by strategic initiatives aimed at enhancing operational efficiency and meeting the increasing demand for complex biologics and therapeutics. As pharmaceutical companies face mounting pressure to accelerate drug development timelines and navigate stringent regulatory environments, many are turning to CDMOs for their specialized manufacturing capabilities. This shift is characterized by a growing trend towards end-to-end service models, where CDMOs offer comprehensive solutions that encompass everything from active pharmaceutical ingredient development to final product manufacturing.
Company Name |
Type of Development |
Month |
Year |
Description |
Vetter Pharma International GmbH |
Expansion |
June |
2024 |
The company announced its plan to set up new facilities in the U.S. and Germany. This expansion is likely to leverage the company’s capacity for clinical manufacturing and related services. |
Alcami Corporation |
Partnership |
March |
2024 |
The company partnered with Tanvex CDMO, enhancing its capabilities in biologics manufacturing. Alcami would leverage its expertise in sterile filling, labeling, and packaging, while Tanvex would contribute its high-throughput bulk drug substance development services. The partnership aimed to expedite the delivery of sterile injectables, addressing the increasing demand for specialty therapeutics and complex biologics. |
Kühne Holding AG |
Acquisition |
April |
2024 |
The company signed an agreement to acquire Anova Group's pharmaceutical CDMO, further expanding its portfolio in healthcare and pharmaceuticals. |
Partnerships, acquisitions, and expansions are becoming essential strategies for CDMOs to bolster their production capacities and expand their service offerings, ultimately positioning themselves as critical players in the evolving landscape of sterile injectables.
Boehringer Ingelheim's reputation, technological capabilities, and global reach position it as a strong player in the sterile injectables CDMO market. However, it must address challenges like competition, cost sensitivity, and evolving client needs while capitalizing on growth opportunities in biologics, emerging markets, and innovative delivery systems.
An in-depth analysis shall be provided for below listed 30 Sterile Injectable CDMOs:
ACS DOBFAR
Aenova Group
Alcami Corporation
Ajinomoto Bio-Pharma
Ardena Holding NV
Argonaut Manufacturing Services
Ascendia Pharmaceuticals
ASPEN
Aurigene Pharmaceutical Services
Axcellerate Pharma
Boehringer Ingelheim International GmbH
Baxter
BioConnection Bv
Bora Pharmaceuticals
Syngene International Ltd.
Terumo Europe NV
TAKATA SEIYAKU CO., LTD
WuXi Biologics
Piramal Pharma Solutions
Vetter Pharma International GmbH
Recipharm AB
Fresenius Kabi Contract Manufacturing (Fresenius Kabi AG)
Unither Pharmaceuticals
FAMAR Health Care Services
PCI Pharma Services
IDT Biologika GmbH
Fareva Group
Eurofins Scientific
Torbay Pharmaceuticals
Pfizer CentreOne (Pfizer Inc.)
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent..."